Solta Medical Reports First Quarter 2009 Revenue of $25.2 Million
“Our first quarter performance reflects the successful integration of our Reliant acquisition as demonstrated by a nearly 50/50 split in revenue derived from our Thermage and Fraxel product lines,” said
The Company reported a net loss of
The Company’s reported results for the first quarter of 2009 include non-cash acquisition-related charges of
“On a pro forma combined basis as if the acquisition of Reliant was in effect from
“Also important to note, in March we secured a long-term bank credit facility for
Financial Goals for 2009
The Company reiterated the following financial goals for 2009:
- Realize approximately
$19 million in cost synergies as a result of the acquisition of Reliant Technologies, Inc. - Generate positive cash flow from operations and positive non-GAAP EBITDA for the full year
- Achieve a non-GAAP gross margin of 70% for the year excluding non-cash amortization charges and other non-cash purchase price related adjustments
Non-GAAP Presentation
To supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross profit, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of purchase price related adjustments, severance costs, and stock-based compensation expenses, all net of income taxes. The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company’s ongoing operating results and trends, compared with historical results. This presentation is also consistent with management’s internal use of the measures, which it uses to measure the performance of ongoing operating results, against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.
Conference Call Information
Solta Medical will host a conference call and webcast today,
A taped replay of the conference call will also be available beginning approximately one hour after the call’s conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers. Both callers will need to use the Passcode 11130432#. To access the live webcast of the call, go to Solta Medical’s website at www.solta.com and click on Investor Relations. An archived webcast will also be available at www.solta.com.
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients which enhance and expand the practice of medical aesthetics for physicians.
The company offers products to address aging skin under the industry’s two premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed in nearly 80 countries. Thermage and Fraxel are the perfect complement for any aesthetic practice. For more information about Solta Medical, call 877-782-2286 or log on to www.Solta.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our expectations regarding the market environment, the adequacy of our financial resources and our financial goals for 2009. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical’s actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the possibility that the development and release of new products and initiatives do not proceed as anticipated, the market for the sale of these new products and initiatives does not develop as expected, the remaining risks and uncertainties with the integration process, the risks related to our future liquidity if we fail to achieve adequate levels of revenue or sustained profitability, if unanticipated expenses or other uses of cash arise or if we are not able to maintain compliance with borrowing facility covenants and the risks relating to Solta Medical’s ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical’s business and its financial results are detailed in its Form 10-K for the year ended
Solta Medical, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands of dollars, except share and per share data)
(unaudited)
Three Months Ended
March 31,
2009 2008
Net revenue $25,245 $16,231
Cost of revenue 11,507 4,358
Gross margin 13,738 11,873
Operating expenses:
Sales and marketing 10,475 7,422
Research and development 3,916 2,731
General and administrative 4,318 4,552
Total operating expenses 18,709 14,705
Loss from operations (4,971) (2,832)
Interest and other income 261 603
Interest and other expenses (47) -
Loss before income taxes (4,757) (2,229)
Provision for income taxes (18) (8)
Net loss $(4,775) $(2,237)
Net loss per share - basic and
diluted $(0.10) $(0.09)
Weighted average shares
outstanding used in calculating
net loss per share:
Basic and diluted 47,758,823 23,630,842
Solta Medical, Inc.
NON-GAAP RECONCILIATION OF GROSS MARGIN, NET LOSS AND NET LOSS PER SHARE
(in thousands, except share and per share data)
(unaudited)
Three Months Ended
March 31,
2009 2008
GAAP Gross margin $13,738 $11,873
Non-GAAP adjustments to gross margin:
Purchase price related adjustments 2,976 -
Stock-based compensation 53 43
Non-GAAP gross margin 16,767 11,916
Non-GAAP gross margin as % of sales 66% 73%
GAAP loss from operations: $(4,971) $(2,832)
Non-GAAP adjustments to loss from
operations:
Purchase price related adjustments 3,292 -
Severance expenses 118 -
Merger-related costs - 969
Stock-based compensation 789 979
Non-GAAP loss from operations (772) (884)
Depreciation expenses 725 311
Non-GAAP EBITDA (47) (573)
GAAP net loss $(4,775) $(2,237)
Non-GAAP adjustments to net loss:
Purchase price related adjustments,
net of taxes 3,292 -
Severance expenses, net of taxes 118 -
Merger-related costs, net of taxes - 969
Stock-based compensation, net of taxes 789 979
Non-GAAP net loss $(576) $(289)
GAAP net loss per share $(0.10) $(0.09)
Non-GAAP adjustments to net loss
per share:
Purchase price related adjustments 0.07 -
Severance expenses, net of taxes 0.00 -
Merger-related costs, net of taxes - 0.04
Stock-based compensation 0.02 0.04
Non-GAAP net loss per share $(0.01) $(0.01)
Weighted average shares outstanding
used in calculating GAAP and
non-GAAP net loss per share 47,758,823 23,630,842
Solta Medical, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands of dollars, except share and per share data)
(Unaudited)
March 31, December 31,
2009 2008
ASSETS
Current assets:
Cash and cash equivalents $8,974 $7,556
Marketable investments 8,094 17,870
Accounts receivable, net 12,854 5,119
Inventories, net 13,333 18,304
Prepaid expenses and other current assets 3,834 4,074
Total current assets 47,089 52,923
Property and equipment, net 6,438 6,841
Purchased intangible assets, net 39,948 40,999
Goodwill 48,257 48,158
Other assets 217 247
Total assets $141,949 $149,168
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Accounts payable $6,083 $8,080
Accrued liabilities 11,741 11,085
Accrued restructuring 1,371 3,549
Current portion of deferred revenue 4,089 3,658
Short-term margin account borrowings 5,620 12,399
Line of credit obligation 3,750 -
Current portion of term loan 1,031 -
Customer deposits 363 288
Total current liabilities 34,048 39,059
Deferred revenue, net of current portion 512 688
Term loan, net of current portion 1,969 -
Non-current tax liabilities 1,507 1,464
Other liabilities 125 133
Total liabilities 38,161 41,344
Stockholders' equity:
Common stock, $0.001 par value:
100,000,000 shares authorized
47,758,823 shares issued and
outstanding at March 31, 2009 and
December 31, 2008 48 48
Additional paid-in capital 166,468 165,680
Deferred stock-based compensation (1) (2)
Accumulated other comprehensive loss (50) -
Accumulated deficit (62,677) (57,902)
Total stockholders' equity 103,788 107,824
Total liabilities and stockholders'
equity $141,949 $149,168
SOURCE Solta Medical, Inc.